NewsBenzingaUBS belässt 10x Genomics auf „Neutral“ und senkt das Kursziel auf 61 US-Dollar UBS belässt 10x Genomics auf „Neutral“ und senkt das Kursziel auf 61 US-Dollar Benzinga 2026.11.06 23:14 (GMT+0) Open on Benzinga Other news UBS Maintains Neutral on Liberty Media, Raises Price Target to $1116 UBS Maintains Neutral on Tripadvisor, Lowers Price Target to $9 Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61 UBS Maintains Neutral on Veeva Systems, Raises Price Target to $325 UBS Upgrades Jinko Holdings to Buy, Lowers Price Target to $17
